GlassScriptPhysician profile
Ara Sadaniantz
NPI 1992766679
$26,656.57
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $6,017 · 2021: $956.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13,851.23 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $9,972.31 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $621.97 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.82 | 2019-2021 | |
| Amarin Pharma, INC. | $434.52 | 2019-2021 | |
| Boston Scientific Corporation | $183.58 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $176.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $145.41 | 2019-2021 | |
| Medtronic Vascular, INC. | $128.69 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $122.84 | 2019-2021 | |
| Medtronic, INC. | $117.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $74.47 | 2019 | |
| Esperion Therapeutics, INC. | $71.76 | 2020-2021 | |
| Daiichi Sankyo INC. | $66.79 | 2021 | |
| Pfizer INC. | $65.66 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36.87 | 2020 | |
| Astellas Pharma US INC | $28.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ara Sadaniantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.